Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. 6Y4.F

VICORE PHARMA HOLDING AB (6Y4 F) stock market data APIs

€1.542 0(0%) as of July 26, 2024
Price chart is built with Anychart

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. Vicore Pharma Holding AB (publ) has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

VICORE PHARMA HOLDING AB Financial Data Overview

1.542
1.542
-
1.542
1.542
1.056-2.005
179 M
112 M
104 M
0.739
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '6Y4',
Type: 'Common Stock',
Name: 'VICORE PHARMA HOLDING AB',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: 'SE0007577895',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

VICORE PHARMA HOLDING AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 104 M
  • EBITDA -225 860 000
  • Earnings Per Share -0.18
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get VICORE PHARMA HOLDING AB Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get VICORE PHARMA HOLDING AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get VICORE PHARMA HOLDING AB latest news via APIs

Vicore Pharma publishes the Annual Report for 2020

GOTHENBURG, Sweden, April 15, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibr...
  • ANNUAL REPORT
  • IDIOPATHIC PULMONARY FIBROSIS
  • VICORE PHARMA HOLDING AB

Vicore Pharma publishes the Annual Report for 2020

GOTHENBURG, Sweden, April 15, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibr...
  • ANNUAL REPORT
  • IDIOPATHIC PULMONARY FIBROSIS
  • VICORE PHARMA HOLDING AB
Do you have any questions?
support@eodhistoricaldata.com